Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry - FDA Guidance Document

Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry - FDA Guidance Document | Global Key Solutions